177 related articles for article (PubMed ID: 36330105)
1. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes.
Luo Q; Zhou L; Zhou N; Hu M
Front Public Health; 2022; 10():1016937. PubMed ID: 36330105
[TBL] [Abstract][Full Text] [Related]
2. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
3. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
Valentine WJ; Palmer AJ; Lammert M; Nicklasson L; Foos V; Roze S
Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China.
Palmer JL; Beaudet A; White J; Plun-Favreau J; Smith-Palmer J
Adv Ther; 2010 Nov; 27(11):814-27. PubMed ID: 21061114
[TBL] [Abstract][Full Text] [Related]
7. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
Farshchi A; Aghili R; Oskuee M; Rashed M; Noshad S; Kebriaeezadeh A; Kia M; Esteghamati A
BMC Endocr Disord; 2016 Jun; 16(1):35. PubMed ID: 27278922
[TBL] [Abstract][Full Text] [Related]
8. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes.
Shafie AA; Gupta V; Baabbad R; Hammerby E; Home P
Diabetes Res Clin Pract; 2014 Nov; 106(2):319-27. PubMed ID: 25305133
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.
Evans M; Gundgaard J; Hansen BB
Diabetes Ther; 2016 Dec; 7(4):809-823. PubMed ID: 27553066
[TBL] [Abstract][Full Text] [Related]
12. Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.
Onishi Y; Yamada K; Zacho J; Ekelund J; Iwamoto Y
J Diabetes Investig; 2017 Mar; 8(2):210-217. PubMed ID: 27560769
[TBL] [Abstract][Full Text] [Related]
13. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
15. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan.
Hassanein M; Echtay AS; Malek R; Omar M; Shaikh SS; Ekelund M; Kaplan K; Kamaruddin NA
Diabetes Res Clin Pract; 2018 Jan; 135():218-226. PubMed ID: 29183844
[TBL] [Abstract][Full Text] [Related]
16. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
17. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
Palmer JL; Knudsen MS; Aagren M; Thomsen TL
J Med Econ; 2010; 13(2):212-20. PubMed ID: 20350145
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
Valentine WJ; Pollock RF; Plun-Favreau J; White J
Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
